NRXP
NRX Pharmaceuticals, Inc.
$4.14
+2.22%
$146.7M
No data for this timeframe.
Vol
Market Cap$146.7M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (91%)
Inst. Holders5 funds
Inst. Value$2.1M
Inst. Activity1 buys / 2 sells
Reddit Sentiment70° Bullish
SEC Reports3
Press Releases6
Recent Activity
May 18, 2026
SEC
NRx Pharmaceuticals reported Q1 2026 EPS of -$0.04, beating consensus of -$0.13 by 69.2%, with net loss narrowing to $1.
PRESS-RELEASE — Impact 6/10
May 14, 2026
SEC
NRx Pharmaceuticals announced it will release Q1 2026 financial results before market open on May 18, 2026, followed by
PRESS-RELEASE — Impact 2/10
Feb 24, 2026
SEC
NRx Pharmaceuticals, Inc. filed a supplement to its definitive proxy statement for its 2026 annual meeting, correcting t
DEFA14A — Impact 3/10
Jan 27, 2026
Insider
Casper Joseph Michael sold 100,000 shares
Chief Operating Officer @ $0.00 ($0.00)
Inst.
VANGUARD GROUP INC — ADD
729,842 shares ($2.0M)
Inst.
TWO SIGMA INVESTMENTS, LP — TRIM
17,436 shares ($47.3K)
Jun 5, 2026
Press
NRx Pharmaceuticals announced the presentation of a peer-reviewed poster at the 2026 ASCP conference showing that IV ket
Impact 7/10
Jun 5, 2026
fda
NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.
<p align="justify">MIAMI, June 05, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq:NRXP, “the
Price Targets
$42.00
+914.5% upside
Strong Buy
Current $4.14
Low $25.00
Median $47.00
High $49.00
4 analysts
$25.00
$49.00
Analyst Ratings
3Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 5, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Apr 27, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Apr 27, 2026 | Ascendiant Capital | MAINTAIN | Buy → Buy |
| Apr 23, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Apr 20, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.13 ▼ -750.0% | $-0.13 — $-0.13 | 87% YoY | 1 |
| Next Q | $-0.08 ▼ -300.0% | $-0.08 — $-0.08 | 84% YoY | 1 |
| Current FY | $-0.36 ▼ -376.9% | $-0.36 — $-0.36 | 73% YoY | 1 |
| Next FY | $0.50 | $0.50 — $0.50 | 239% YoY | 1 |
Latest Reports
BULLISH
Press
7/10
NRx Pharmaceuticals announced the presentation of a peer-reviewed poster at the 2026 ASCP conference showing that IV ket
Jun 5, 2026
BULLISH
PRESS-RELEASE
6/10
NRx Pharmaceuticals reported Q1 2026 EPS of -$0.04, beating consensus of -$0.13 by 69.2%, with net loss narrowing to $1.
May 18, 2026
NEUTRAL
PRESS-RELEASE
2/10
NRx Pharmaceuticals announced it will release Q1 2026 financial results before market open on May 18, 2026, followed by
May 14, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $2.0M | ADD |
| TWO SIGMA INVESTMENTS, LP | $47.3K | TRIM |
| MORGAN STANLEY | $27.2K | DOUBLED |
| BANK OF AMERICA CORP | $8.8K | — |
| WELLS FARGO & COMPANY/MN | $5.4K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jan 27, 2026 | Casper Joseph | A | $0.00 |
Reddit Sentiment
70°
Bullish
Bearish
Neutral
Bullish
5 institutional holders with $2.1M total value (762,546 shares) as of 2025-Q4. Top holders: VANGUARD, TWO, MORGAN. Net selling activity: 2 institutions trimmed/exited vs 1 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 729,842 | $2.0M | 95.7% | ADD +36.4% |
| 2 | TWO SIGMA INVESTMENTS, LP | 17,436 | $47.3K | 2.3% | TRIM -66.7% |
| 3 | MORGAN STANLEY | 10,029 | $27.2K | 1.3% | DOUBLED +152.0% |
| 4 | BANK OF AMERICA CORP /DE/ | 3,239 | $8.8K | 0.4% | — |
| 5 | WELLS FARGO & COMPANY/MN | 2,000 | $5.4K | 0.3% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | ADD | 534,956 | 729,842 | +36.4% | $2.0M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 52,332 | 17,436 | -66.7% | $47.3K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 128,175 | 0 | -100.0% | $0.00 | 2025-Q4 |
| UBS Group AG | ADD | 121,608 | 152,848 | +25.7% | $504.4K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 128,175 | — | $423.0K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 31,452 | 52,332 | +66.4% | $172.7K | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 4,396 | 11,080 | +152.0% | $36.6K | 2025-Q3 |
| UBS Group AG | DOUBLED | 105 | 121,608 | +115717.1% | $396.4K | 2025-Q2 |
| MORGAN STANLEY | TRIM | 11,896 | 4,396 | -63.0% | $14.3K | 2025-Q2 |
| VANGUARD GROUP INC | ADD | 240,316 | 388,925 | +61.8% | $797.3K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 30,146 | — | $61.8K | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 4,396 | 11,896 | +170.6% | $24.4K | 2025-Q1 |
| UBS Group AG | TRIM | 150 | 105 | -30.0% | $215.00 | 2025-Q1 |
| FMR LLC | NEAR_EXIT | 150 | 37 | -75.3% | $76.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | EXIT | 22,200 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 36,300 | 22,200 | -38.8% | $48.8K | 2024-Q4 |
| UBS Group AG | DOUBLED | 38 | 150 | +294.7% | $330.00 | 2024-Q4 |
1 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jan 27, 2026 | Casper Joseph Michael | Chief Operating Officer | A | 100,000 | $0.00 | $0.00 |
3 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 3.7/10.
BULLISH
PRESS-RELEASE
6/10
NRx Pharmaceuticals reported Q1 2026 EPS of -$0.04, beating consensus of -$0.13 by 69.2%, with net l
May 18, 2026
NEUTRAL
PRESS-RELEASE
2/10
NRx Pharmaceuticals announced it will release Q1 2026 financial results before market open on May 18
May 14, 2026
NEUTRAL
DEFA14A
3/10
NRx Pharmaceuticals, Inc. filed a supplement to its definitive proxy statement for its 2026 annual m
Feb 24, 2026
BULLISH
7/10
NRx Pharmaceuticals announced the presentation of a peer-reviewed poster at the 2026 ASCP conference
Jun 5, 2026
BEARISH
6/10
NRx Pharmaceuticals closed an underwritten public offering of common stock at $3.50 per share, raisi
Jun 4, 2026
BEARISH
6/10
NRx Pharmaceuticals priced an underwritten public offering of 5,714,286 shares at $3.50/share, with
Jun 3, 2026
BEARISH
6/10
NRx Pharmaceuticals announced an underwritten public offering of common stock, with an option for un
Jun 2, 2026
BULLISH
6/10
NRx Pharmaceuticals' subsidiary Hope Therapeutics partnered with Emobot Health to deploy an AI-power
Mar 30, 2026
NEUTRAL
3/10
NRx Pharmaceuticals announced it will host a conference call to discuss its fiscal year 2025 financi
Mar 19, 2026
Current analyst consensus: Strong Buy (91% buy). Based on 11 analysts: 3 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$42.00 mean target
+914.5% upside
Strong Buy (1.00)
$25.00 Low
$49.00 High
| Metric | Value |
|---|---|
| Current Price | $4.14 |
| Target Low | $25.00 |
| Target Mean | $42.00 |
| Target Median | $47.00 |
| Target High | $49.00 |
| # Analysts | 4 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.13 | $-0.13 | $-0.13 | 86.7% | -750.0% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.08 | $-0.08 | $-0.08 | 84.2% | -300.0% | 0↑ 1↓ | $0.0B | 616.5% | 1 |
| Current FY 2026-12-31 |
$-0.36 | $-0.36 | $-0.36 | 73.1% | -376.9% | 0↑ 1↓ | $0.0B | 960.1% | 1 |
| Next FY 2027-12-31 |
$0.50 | $0.50 | $0.50 | 238.9% | — | — | $0.2B | 1471.4% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.130 | |
| 7d ago | $0.020 | -0.150 |
| 30d ago | $0.020 | -0.150 |
| 60d ago | $0.020 | -0.150 |
| 90d ago | $0.020 | -0.150 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 5, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Apr 27, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 27, 2026 | Ascendiant Capital | MAINTAIN | Buy | Buy |
| Apr 23, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Apr 20, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 24, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 24, 2026 | BTIG | REITERATE | Buy | Buy |
| Mar 17, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 16, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 9, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 3, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 18, 2026 | BTIG | REITERATE | Buy | Buy |
| Feb 17, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 15, 2026 | BTIG | REITERATE | Buy | Buy |
| Jan 5, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 2, 2026 | Ascendiant Capital | MAINTAIN | Buy | Buy |
| Dec 16, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| May 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% | |
| Apr 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% | |
| Mar 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% | |
| Feb 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% | |
| Jan 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
70°
Bullish
Bearish
Neutral
Bullish
6 mentions
4 bullish
0 bearish
4 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 20, 2026 | 2 | 58° Warm | 1 | 0 | 2 |
| Apr 20, 2026 | 2 | 58° Warm | 1 | 0 | 2 |
| Apr 16, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 16, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Jun 5, 2026
fda
NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.
<p align="justify">MIAMI, June 05, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq:NRXP, “the Company”) announces the presentation of a peer-re
Jun 4, 2026
offering
NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option
Offering was led by B Group Capital with significant participation from, among others, Columbia Threadneedle Investments, Corbets Capital, Venture 76,
Jun 3, 2026
offering
NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
<p align="justify">WILMINGTON, Del., June 03, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals” or the “Compa
Jun 3, 2026
short_volume
Short Volume: NRXP — 59.0% short (1.0M / 1.7M)
Short: 1,014,598 | Exempt: 93,414 | TRF Vol: 1,719,512 | Short Ratio: 59.0% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
activist
NRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
<p align="justify">WILMINGTON, Del., June 02, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals” or the “Compa
Jun 2, 2026
short_volume
Short Volume: NRXP — 66.4% short (0.5M / 0.7M)
Short: 485,308 | Exempt: 1,278 | TRF Vol: 730,953 | Short Ratio: 66.4% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: NRXP — 55.1% short (0.4M / 0.8M)
Short: 427,992 | Exempt: 8,164 | TRF Vol: 777,240 | Short Ratio: 55.1% | Off-exchange volume (dark pool + OTC)
May 28, 2026
routine
NRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026
<p>SARASOTA, Fla. and PARIS, May 28, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hEHMx1FdMZS3HUzDYX0BsaHafdgxm8Q8I8
May 18, 2026
earnings
NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update
<p align="justify">Key highlights from the first quarter of operations under the expanded management team include the following:</p>
May 14, 2026
earnings
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate Update
<p align="left">WILMINGTON, Del., May 14, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”),
May 13, 2026
earnings_calendar
NRXP Q1 2026 Earnings Scheduled — 2026-05-13
May 11, 2026
short_volume
Short Volume: NRXP — 67.2% short (0.5M / 0.7M)
Short: 457,509 | Exempt: 539 | TRF Vol: 680,927 | Short Ratio: 67.2% | Off-exchange volume (dark pool + OTC)
May 6, 2026
short_volume
Short Volume: NRXP — 62.9% short (0.3M / 0.5M)
Short: 343,975 | Exempt: 200 | TRF Vol: 546,608 | Short Ratio: 62.9% | Off-exchange volume (dark pool + OTC)
Apr 27, 2026
short_volume
Short Volume: NRXP — 74.2% short (0.6M / 0.8M)
Short: 594,642 | Exempt: 7,600 | TRF Vol: 801,062 | Short Ratio: 74.2% | Off-exchange volume (dark pool + OTC)
Apr 20, 2026
other
NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality
<p>WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq:NRXP) welcomes the newly-signed Executive Order: ACCELERATING ME